Skip to main content

Table 2 Timing and dose of DES exposure in relation to urogenital abnormalities

From: Urogenital abnormalities in men exposed to diethylstilbestrol in utero: a cohort study

 

Cases/Total

Risk ratio*

95% Confidence interval

Cryptorchidism

   

   Timing of DES exposure

   

Began after 11th wk

8/451

1.1

0.5-2.5

Began before 11th wk

29/625

2.9

1.6-5.2

   Cumulative dose < 5 g

7/231

1.9

0.8-4.5

   Cumulative dose ≥ 5 g

20/389

3.2

1.7-6.0

Epididymal cyst

   

   Timing of DES exposure

   

Began after 11th wk

17/451

2.0

1.0-3.8

Began before 11th wk

38/625

3.5

2.0-6.0

   Cumulative dose < 5 g

11/231

2.7

1.3-5.7

   Cumulative dose ≥ 5 g

28/389

4.0

2.3-7.1

Inflammation of testes

   

   Timing of DES exposure

   

Began after 11th wk

16/451

2.1

1.1-4.2

Began before 11th wk

30/625

3.0

1.7-5.4

   Cumulative dose < 5 g

9/231

2.0

1.1-3.8

   Cumulative dose ≥ 5 g

23/389

3.2

1.7-5.8

  1. *Risk ratios adjusted for year of birth and cohort.